News – Page 1127 – Endpoints News

Tesaro shares skid lower as AstraZeneca wows with PhIII data on PARP drug for ovarian cancer

9 years ago

On again, ex-Google superstar Bill Maris is said to bankroll a $100M biotech fund

9 years ago

Sanofi and Regeneron score early access for dupilumab in UK; Sanders skewers Sanofi on Zika vaccine

9 years ago

Pushing ahead with cancer drug research, Peloton brings its latest round to $75M

9 years ago

Amgen steers PCSK9 blockbuster hopeful through another promising PhIII, but the critical test is looming

9 years ago

Allergan antes up $90M in a landmark CRISPR/Cas9 collaboration with Editas on eye diseases

9 years ago

Dogged by setbacks and an air of crisis, Alexion Pharma opts to restructure, slashing staff

9 years ago

Watch out Pfizer, Novartis’ LEE011 bags quick OK for frontline use against breast cancer

9 years ago

Daiichi Sankyo forges $12M pact for GPCR pain program with Heptares; Incyte shares jump on latest takeover chatter

9 years ago

Roche and Mylan settle a scrap over Herceptin, clearing path to a global launch of a knockoff drug

9 years ago

Celgene embraces MTAP cancer deal with fast-moving collaborator Agios

9 years ago

With its lead antibiotic under a cloud, Cempra asks Morgan Stanley for help with a strategic review

9 years ago

Biopharma execs give Scott Gottlieb’s nomination for FDA commish (almost) a standing O in Endpoints poll

9 years ago

Pfizer vet Germano makes quick exit from Intrexon as hands-on billionaire Kirk reorganizes biotech

9 years ago

FDA orders Karyopharm to halt enrollment for all selinexor trials, citing incomplete safety warning

9 years ago

President Trump names Scott Gottlieb as the next FDA commissioner. What now?

9 years ago

Gottlieb continues to be Trump's leading candidate for FDA; BeyondSpring completes unusual IPO

9 years ago

Bristol-Myers makes a decisive move to fix its R&D problem; Let's not underestimate Trump now

9 years ago

Argos Therapeutics slashes staff in the wake of the latest cancer vaccine flop

9 years ago

Meacham’s manifesto to Gilead: It’s time to do something dramatic — buy, bag or burn

9 years ago

Tocagen shoots for $86 million IPO, spotlighting a high-risk shot at a quick OK for brain cancer therapy

9 years ago

The new CEOs in biopharma are joining the big players at the billion-dollar chip table

9 years ago

Servier, Pfizer get FDA OK to start US testing of an off-the-shelf CAR-T from Cellectis

9 years ago

OncoResponse wraps Series A with $22.5M; Plotting IPO, BerGenBio partners with Merck on cancer combos

9 years ago

First page Previous page 1124 1125 112611271128 1129 1130 Next page Last page